Pacira (PCRX) BioSciences announced an exclusive worldwide license and collaboration agreement with AmacaThera for the development and commercialization of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. Under the terms of the agreement, Pacira will fund clinical development through to commercial launch and the companies will collaborate on Phase 2 clinical development. AmacaThera will receive an upfront payment of $5 million with the potential for future development- and sales-based milestone payments and a tiered royalty on future net sales.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira presents updated three-year results of PCRX-201
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
- Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know
- Pacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment